Acacia Pharma Ltd   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge United Kingdom (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2009
NCT00895726
First Marketed Drug
2020
amisulpride (BARHEMSYS)
First NDA Approval
2020
amisulpride (BARHEMSYS)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ACACIA | Acacia Pharma Ltd | ACACIA PHARMA LTD

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cachexia (Phase 2)

Nausea (Phase 3)

Postoperative Nausea and Vomiting (Phase 3)

Vomiting (Phase 3)

Wasting Syndrome (Phase 2)

Xerostomia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 10